Intrinsic Therapeutics said today that it raised a $49 million debt-and-equity round for the Barricaid annular closure device for discectomies that it’s developing. The Boston-based company said the round consisted of a $28 million equity financing led by New Enterprise Assoc. and Delos Capital, plus a $21 million debt facility with CRG. Other backers included Greenspring Associates, Quadrille […]
CRG
ViewRay raises $14m in private placement
ViewRay (NSDQ:VRAY) said today that it raised nearly $14 million in a private placement as it gears up to launch its MRIdian linear accelerator, saying it expects to win regulatory nods in the U.S. and overseas by the end of the year. Cleveland-based ViewRay said the round was led by existing backers OrbiMed Advisors, Xeraya Capital and Kearny Venture […]
Navidea lands $60m for Lymphoseek
Ceterix lands $35m for suture device
Ceterix Orthopaedics said last week that it took out a $35 million term loan with CRG it plans to use to advance its NovoStitch suture passing device for surgeries to repair torn menisces in the knee.
Menlo Park, Calif.-based Ceterix said the NovoStitch device is designed to help surgeons place sutures in patterns that used to require open procedures or weren’t possible at all.
Astute Medical to receive up to $30M from CRG for kidney-injury test | Medtech funding for the week of October 13, 2014
FDA nod triggers $30m milestone for Astute Medical
Astute Medical said it’s in line to receive up to $30 million under a standing loan agreement from funding partner CRG to commercialize its recently approved NephroCheck kidney-injury test, and could receive an additional $10 million if it hits certain revenue milestones.
